The Use of Transcutaneous Magnetic Stimulation to Treat Painful Diabetic Neuropathy

Rao, Vishnu P; Satyarengga, Medha; Lamos, Elizabeth M.; Munir, Kashif M.

doi:10.1177/19322968211026943

Cited by 3 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peripherally delivered TCMS appears to be a safe treatment modality for DPN. The TCMS device used in this study shares technology with an FDA transcranial magnetic stimulation device for migraine treatment in which no notable adverse events have been observed 28 . As expected, no significant adverse events related to TCMS treatment were detected in this trial during the 28‐day follow‐up period.…”

Section: Discussionsupporting

confidence: 61%

“…The findings from this study are in stark contrast to those from our previous pilot study. 28 Although the preceding pilot study did not include a placebo arm, there was a 78% pain reduction immediately following TCMS therapy. This is much greater than 34% reduction observed in this study.…”

Section: Discussionmentioning

confidence: 99%

“…The TCMS treatment plan was based on preliminary data, which demonstrated significant decreases in pain lasting one week after a one-time TCMS treatment to the feet. 28 Treatments were administered on days 0, 7, 14, and 21 by study investigators utilizing the Pulse V1.0 device (Figure 1). TCMS treatment consisted of four weekly sessions of 1.2 Tesla magnetic pulses delivered to the plantar surface of the foot.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of recurrent transcutaneous magnetic stimulation in the treatment of diabetic peripheral neuropathy: Multicenter randomized trial

et al. 2023

Self Cite

View full text Add to dashboard Cite

AimsTranscutaneous magnetic stimulation (TCMS) is successful in decreasing pain in several neurologic conditions. This multicenter parallel double‐blind phase II clinical trial is a follow‐up to a pilot study that demonstrated pain relief in patients with diabetic peripheral neuropathy (DPN) treated with TCMS.MethodsThirty‐four participants with confirmed DPN and baseline pain score ≥ 5 were randomized to treatment at two sites. Participants were treated with either TCMS (n = 18) or sham (n = 16) applied to each foot once a week for four weeks. Pain scores using the Numeric Pain Rating Scale after 10 steps on a hard floor surface and answers to Patient‐Reported Outcomes Measurement Information System pain questions were recorded by participants daily for 28 days.ResultsThirty‐one participants completed the study and were analyzed. Average pain scores decreased from baseline in both the groups. The difference in pain scores between TCMS and sham treatments was −0.55 for morning, −0.13 for evening, and −0.34 overall, below the pre‐determined clinically relevant difference of −2. Moderate adverse events that resolved spontaneously were experienced in both treatment arms.ConclusionIn this two‐arm trial, TCMS failed to demonstrate a significant benefit over sham in patient reported pain suggesting a substantial placebo effect in our previous pilot study.Trial registrationTCMS for the Treatment of Foot Pain Caused By Diabetic Neuropathy, https://clinicaltrials.gov/ct2/show/NCT03596203, ID‐NCT03596203.

show abstract

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of recurrent transcutaneous magnetic stimulation in the treatment of diabetic peripheral neuropathy: Multicenter randomized trial

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…This correlates to about a 78% improvement from baseline, with five participants reporting a 100% improvement. Pain reductions were significant up to 7-day post-treatment ( P = 0.0295) [ 78 ]. While these studies showed very promising results in patients who were responsive to treatment, studies with higher patient participation and longitudinal studies are needed before determining clinical efficacy and implementation.…”

Section: Discussionmentioning

confidence: 99%

Recent Advances in Management of Neuropathic, Nociceptive, and Chronic Pain: A Narrative Review with Focus on Nanomedicine, Gene Therapy, Stem Cell Therapy, and Newer Therapeutic Options

Kataria,

Patel,

Yabut

et al. 2024

Curr Pain Headache Rep

View full text Add to dashboard Cite

Purpose of Review This manuscript summarizes novel clinical and interventional approaches in the management of chronic, nociceptive, and neuropathic pain. Recent Findings Pain can be defined as a feeling of physical or emotional distress caused by an external stimulus. Pain can be grouped into distinct types according to characteristics including neuropathic pain, which is a pain caused by disease or lesion in the sensory nervous system; nociceptive pain, which is pain that can be sharp, aching, or throbbing and is caused by injury to bodily tissues; and chronic pain, which is long lasting or persisting beyond 6 months. With improved understanding of different signaling systems for pain in recent years, there has been an upscale of methods of analgesia to counteract these pathological processes. Novel treatment methods such as use of cannabinoids, stem cells, gene therapy, nanoparticles, monoclonal antibodies, and platelet-rich plasma have played a significant role in improved strategies for therapeutic interventions. Summary Although many management options appear to be promising, extensive additional clinical research is warranted to determine best practice strategies in the future for clinicians.

show abstract

“…Standard electrical PNS devices have been utilized for both acute and chronic pain conditions. Electrical PNS has been utilized to offer substantial analgesia in pain conditions including complex regional pain syndrome, postherpetic neuralgia, cranial neuralgias, migraines and cluster headaches, amputee pain, back pain, cancer-related pain 8 as well as painful diabetic neuropathy (PDN) and knee osteoarthritis [13][14][15] related pain. It appears that our patients represented a wide array of similar patients and further studies will validate the similarly expanded role for mPNS.…”

Section: Discussionmentioning

confidence: 99%

Magnetic Peripheral Nerve Stimulation (mPNS) for Chronic Pain

Bedder¹,

Parker²

2023

JPR

View full text Add to dashboard Cite

To assess magnetic peripheral nerve stimulation (mPNS) for the treatment of chronic or chronic and intractable neuropathic pain with a retrospective review case series. Patients and methods: Twenty-four patients with predominantly neuropathic post-traumatic or postoperative pain were treated as per protocol and followed for 3 months. Results: Data were analyzed as an observational, one-armed, convenience sample. Graphical evidence backed up by a mixed model for repeated measures statistical analysis showed a highly significant reduction of pain at one month out from initial treatment with mPNS. At one month, there was a 3.8 average reduction in pre-pain scores using a visual analogue scale (VAS), and that relief was generally durable measured out to three months. Two-thirds of patients, deemed responders, showed an 87% reduction in pain. Opioid reduction was seen in 58.3% of responders as well. Conclusion: mPNS appears promising for the treatment of chronic or chronic and intractable neuropathic pain for many of the same indications as traditional electrical peripheral nerve stimulation (PNS). No invasive techniques or implants are needed for mPNS.

show abstract

The Use of Transcutaneous Magnetic Stimulation to Treat Painful Diabetic Neuropathy

Cited by 3 publications

References 6 publications

Efficacy of recurrent transcutaneous magnetic stimulation in the treatment of diabetic peripheral neuropathy: Multicenter randomized trial

Efficacy of recurrent transcutaneous magnetic stimulation in the treatment of diabetic peripheral neuropathy: Multicenter randomized trial

Recent Advances in Management of Neuropathic, Nociceptive, and Chronic Pain: A Narrative Review with Focus on Nanomedicine, Gene Therapy, Stem Cell Therapy, and Newer Therapeutic Options

Magnetic Peripheral Nerve Stimulation (mPNS) for Chronic Pain

Contact Info

Product

Resources

About